Randomised controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major

Frontiers in Pharmacology

Volumn 5, Issue SEP, 2014, Pages

  Baksi, A John ^a   Pennell, Dudley J ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiac siderosis; Chelation trials; Iron; T2*imaging; Thalassaemia

Indexed keywords

CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

ACUTE HEART FAILURE; AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EYE TOXICITY; FANCONI RENOTUBULAR SYNDROME; GASTROINTESTINAL SYMPTOM; GROWTH RETARDATION; HEARING IMPAIRMENT; HEART FAILURE; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HUMAN; IRON METABOLISM; IRON OVERLOAD; MONOTHERAPY; OTOTOXICITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SKIN MANIFESTATION; SURVIVAL RATE; THALASSEMIA MAJOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

EID: 84907927202     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00217     Document Type: Article

References (24)

1. Baksi AJ, Pennell D. J. T2* Imaging of the Heart: Methods, Applications, and Outcomes. Topics in Magnetic Resonance Imaging (2014) 23: 13-20.
2. Anderson LJ, Holden S, Davies B, et al. Cardiovascular T2* (T2 star) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-9.
3. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8.
4. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ. On T2* magnetic resonance and cardiac iron. Circulation 2011; 123: 1519-28.
5. Carpenter JP, Roughton M, Pennell DJ; Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in ß-thalassemia major. Haematologica 2013; 98: 1368-74.
6. Pennell DJ, Udelson J E, Arai AE, et al. Cardiovascular Function and Treatmentin ß-Thalassemia Major. A Consensus Statement From the American Heart Association. Circulation 2013: 128: 281-308.
7. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-44.
8. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-84.
9. Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, Porter JB, Banya W, He T, Smith GC, Pennell DJ. Relation of myocardial T2* to right ventricular function in thalassaemia major. Eur Heart J 2010; 31: 1648-54.
10. Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson 2012; 14: 8.
11. Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek, Kilinc Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in ß-thalassemia major (CORDELIA). Blood 2014; 123: 1447-54.
12. Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol (2008) 141: 882-90.
13. Xia S, Zhang W, Huang L, Jiang H. Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassaemia: A Meta-Analysis of 16 Randomized Controlled Trials. PLoS ONE (2013) 8(12): e82662.
14. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-20.
15. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, De Marchi D, Midiri M, Maggio A. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol 2006; 76: 183-92.
16. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011; 96: 41-7.
17. Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2013; 8: CD004839.
18. Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30: 239-49.
19. Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006; 85: 315-9.
20. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells, Mol Dis 2006; 36: 21-5.
21. Christoforidis, A., Haritandi, A., Tsatra, I., Tsitourides, I., Karyda, S. & Athanassiou-Metaxa, M. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens. Eur J Haematol 2007; 78: 52-7.
22. Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson 2013; 15: 38.
23. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10: 12.
24. Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10: 42.